Zeo ScientifiX, Inc.

false 0001557376 0001557376 2026-05-27 2026-05-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2026 ZEO SCIENTIFIX, INC. (Exact name of registrant as specified in its charter) Nevada 000-55008 47-4180540 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 3321 College Avenue , Suite 246 Davie , Florida 33314 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (888) 963-7881 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each Class Trading Symbol Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ As used in this Current Report on Form 8-K (this “ Report ”), and unless otherwise indicated, the terms “ the Company ,” “ ZEO ,” “ we ,” “ us ” and “ our ” refer to Zeo ScientifiX, Inc. Item 8.01 Other Events. On May 27, 2026, ZEO issued a press release announcing the formal launch of its Physician-Led Patient Masterclass program designed to help physicians mobilize their patient population and provide critical education to current and potential patients about regenerative medicine. A copy of the press release is included as Exhibit 99.1 to this Report. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 27, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 27, 2026 ZEO SCIENTIFIX, INC. By: /s/ Ian T. Bothwell Ian T. Bothwell Chief Executive Officer and Chief Financial Officer 2